Golden State Wealth Management LLC Boosts Position in Pfizer Inc. (NYSE:PFE)

Golden State Wealth Management LLC raised its position in Pfizer Inc. (NYSE:PFE - Free Report) by 102.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 65,496 shares of the biopharmaceutical company's stock after purchasing an additional 33,176 shares during the period. Golden State Wealth Management LLC's holdings in Pfizer were worth $1,660,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in PFE. Sage Mountain Advisors LLC grew its position in Pfizer by 7.3% during the fourth quarter. Sage Mountain Advisors LLC now owns 20,587 shares of the biopharmaceutical company's stock worth $546,000 after buying an additional 1,404 shares in the last quarter. Brighton Jones LLC boosted its position in shares of Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock valued at $17,677,000 after acquiring an additional 618,117 shares during the last quarter. Acorn Financial Advisory Services Inc. ADV grew its holdings in shares of Pfizer by 32.8% during the fourth quarter. Acorn Financial Advisory Services Inc. ADV now owns 9,288 shares of the biopharmaceutical company's stock worth $246,000 after purchasing an additional 2,292 shares in the last quarter. Aptus Capital Advisors LLC increased its position in shares of Pfizer by 124.0% in the fourth quarter. Aptus Capital Advisors LLC now owns 223,203 shares of the biopharmaceutical company's stock worth $5,922,000 after purchasing an additional 123,543 shares during the last quarter. Finally, Fisher Asset Management LLC raised its stake in Pfizer by 79.5% in the fourth quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company's stock valued at $295,760,000 after purchasing an additional 4,938,209 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Trading Up 0.2%

Pfizer stock traded up $0.04 during trading hours on Thursday, reaching $24.30. The company had a trading volume of 31,721,433 shares, compared to its average volume of 41,253,048. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.26 and a quick ratio of 0.96. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $31.54. The company has a 50-day moving average price of $23.38 and a 200 day moving average price of $24.87. The firm has a market cap of $138.18 billion, a price-to-earnings ratio of 17.61, a P/E/G ratio of 0.88 and a beta of 0.57.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, topping the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. During the same period in the previous year, the firm earned $0.82 earnings per share. The firm's revenue for the quarter was down 7.8% on a year-over-year basis. Equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.08%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's dividend payout ratio (DPR) is 124.64%.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. The Goldman Sachs Group reissued a "neutral" rating and issued a $25.00 price target (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Citigroup reiterated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Guggenheim restated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Finally, UBS Group raised their price objective on Pfizer from $24.00 to $25.00 and gave the company a "neutral" rating in a report on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.